Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

This is the latest in a long battle between medical technology company Masimo and the tech giant, with Apple claiming that an ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings ... All You Need to Know About Masimo Masimo Corp is a global technology company. The company's segment includes healthcare ...

Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring ...

Renowned Healthcare Facility Launches Advanced Wireless Monitoring Technology in the Emergency ... of physiological measurements, including Masimo SET® pulse oximetry, measure-on-inflation ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.